The director of Nigeria’s National Agency for Food and Drug Administration and Control (Nafdac), Mojisola Adeyeye, has divulge that clinical trails for virus cure using chloroquine will continue despite a contemporary move by the WHO to suspend an analogoustrial over welfare concerns.
She told an area broadcaster that although Nafdac didn’t disagree WHO’s conclusions, the choice to continue with the trial was so as to come up with their own data.“I don’t know the information that they’re gazing, whether it’s from the Caucasian population or from the African population. If the information they’re gazing and also the reason for dangle the trials is from Caucasian population, then it should be justified.“But I don’t think we’ve got data from the African population yet, because our genetic frame is different,” she added. Lagos State had Report last week that trials were to begin with the anti_malarial drug.
A number of African countries have also been using the drug to treat COVID-19. Algeria has also said it’ll continue using it for cure. Cameroon’s health minister recently affirmed that chloroquine continued to be the popular drug for treatment.
Medical journal, The Lancet reported on Friday May 22 that patients getting hydroxy chloroquine were dying at higher rates than other covid-19 patients.
The WHO has 3,500 patients from 17 countries enrolled in what it calls the Solidarity Trial. this is often an undertake overseen by the WHO to find new treatments for COVID-19.